PD-L1 (SP142) testing is concordant between Benchmark Ultra and Bond-III stainers

BACKGROUND: Atezolizumab is an inhibitor of programmed death-ligand 1 (PD-L1), used to treat advanced or metastatic bladder cancer, and in trials for non-invasive disease. In order to be eligible for treatment, patients require a PD-L1 immune cell score ≥ 5%, using the Ventana SP142 PD-L1 assay. Man...

Descripción completa

Detalles Bibliográficos
Autores principales: Compérat, Eva, Oszwald, André, Wasinger, Gabriel, Wacquet, Justine, Rouprêt, Morgan, Cussenot, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Topic Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571218/
https://www.ncbi.nlm.nih.gov/pubmed/34515825
http://dx.doi.org/10.1007/s00345-021-03828-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8571218/
https://www.ncbi.nlm.nih.gov/pubmed/34515825
http://dx.doi.org/10.1007/s00345-021-03828-w

Ejemplares similares